A Multicenter, Open Label Phase I Clinical Trial Evaluating the Safety and Pharmacokinetics of TQB2252 Injection in Subjects With Advanced Malignant Tumors

Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.1 site in 1 country100 target enrollmentNovember 2024

ConditionsAdvanced Cancers

InterventionsTQB2252 injection

Overview

Phase: Phase 1
Intervention: TQB2252 injection
Conditions: Advanced Cancers
Sponsor: Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Enrollment: 100
Locations: 1
Primary Endpoint: Adverse events (AE) rate
Status: Not yet recruiting
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is a multicenter, single arm, and open design Phase I clinical trial aimed at evaluating the safety, Pharmacokinetics (PK) characteristics, immunogenicity, and preliminary efficacy of TQB2252 injection in subjects with advanced malignant tumors.

Registry

clinicaltrials.gov

Start Date

November 2024

End Date

December 2026

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•The subjects voluntarily joined this study, signed an informed consent form, and showed good compliance;
•18 years old ≤ 75 years old (calculated from the date of signing the informed consent form);
•Electrocorticogram (ECOG) score ranges from 0 to 1 points;
•Expected survival is greater than 12 weeks；
•Confirmed to have at least one measurable lesion according to RECIST 1.1 (solid tumor) or Lugano 2014 (lymphoma) criteria；
•Late stage malignant tumor subjects who have failed standard treatment or lack effective treatment；
•Women of childbearing age should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study; Men should agree to use effective contraceptive measures during the study period and for 6 months after the end of the study period.

Exclusion Criteria

•Has experienced or currently has other malignant tumors within the past 5 years prior to the first use of medication;
•There are multiple factors that affect diseases related to intravenous injection and venous blood collection;
•The adverse reactions of previous anti-tumor treatments have not recovered to a Common Terminology Criteria for Adverse Events (CTCAE) v5.0 score of ≤ 1;
•Individuals who have undergone major surgical treatment, significant traumatic injury, or are expected to undergo major surgery during the expected study treatment period within 4 weeks prior to the first use of medication;
•Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first administration;
•An arterial/venous thrombotic event occurred within 6 months prior to the first administration;
•Active viral hepatitis with poor control;
•Active syphilis infected individuals in need of treatment;
•History of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonia, radiation pneumonitis requiring treatment, or clinically symptomatic active pneumonia;
•Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders;

Arms & Interventions

TQB2252 injection

This product is administered via intravenous infusion, with recommended doses of 600mg TQB2223 monoclonal antibody and 200mg penpulimab injection, administered once every 3 weeks.

Intervention: TQB2252 injection

Outcomes

Primary Outcomes

Adverse events (AE) rate

Time Frame: From date of the first dose until the date of 28 days after last dose or new anti-tumor treatment, whichever came first.

The evaluation criteria for the nature and severity of adverse events are based on the National Cancer Institute's CommonTerminology Criteria for Adverse Events (NCI CTCAE version 5.0).

Secondary Outcomes

Progression-free survival (PFS)(up to 2 years)
Time to reach maximum observed plasma concentration (Tmax)(Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4～Cycle 8: pre-dose. (Each cycle is 21 days))
Maximum Plasma Concentration (Cmax)(Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4～Cycle 8: pre-dose. (Each cycle is 21 days))
Elimination half-life (t1/2)(Day1 of Cycle1, Cycle3: within 30 minutes pre-dose, 0.25, 2, 4, 8, 24, 48, 168, 336 hour post dose. Day1 of Cycle2, Cycle4～Cycle 8: pre-dose. (Each cycle is 21 days))
Objective Response Rate (ORR)(up to 2 years)
Disease control rate (DCR)(up to 2 years)
Duration of Response (DOR)(up to 2 years)